$FORR

Do You Use AI Moderators For Customer Research? I’d Love To Hear From You

The article discusses the emerging use of AI moderators in customer research, highlighting their potential to transform qualitative research by enabling scalable insights and overcoming language and time zone barriers. The author, a Forrester analyst, is conducting research to understand how these AI tools work, their most effective use cases, best practices, and pitfalls, and is seeking input from vendors and researchers who have experience with AI-moderated interviews.

Original reporting
Forrester · Senem Guler Biyikli
Published Mar 16, 2026, 4:06 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Mar 16, 2026, 4:30 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
Do You Use AI Moderators For Customer Research? I’d Love To Hear From You — source image
Decision brief

The 30-second read

$FORRNeutralLow
01

Why it matters

While industry-wide adoption may influence investor sentiment towards AI and technology stocks, the direct impact on FORR and CRM remains limited in the short term.

02

Market read

The news underscores technological advancements in AI, with potential long-term benefits for AI-related stocks, but limited immediate trading implications.

03

What to watch

Potential regulatory developments in AI and data privacy could impact industry adoption and stock performance.

Relevance 6/10Timing: low

Background

The article highlights the growing adoption of AI moderators in customer research, reflecting broader technological trends.

Company-level read

Ticker impact

$FORRNeutralMedium confidence
Context

Moderate relevance due to neutral sentiment and low impact on market sentiment.

Expected impact

Minimal to no immediate impact on FORR stock price.

Evidence & confidence

The topic is industry-specific and does not directly influence FORR's financials or market perception.

Market effects

Potential positive sentiment towards technology and AI sectors, with cautious outlook due to industry-specific nature.

Limited regional impact; primarily industry-specific.

Low; the topic is niche and unlikely to influence global markets significantly.

Counterpoint

Some investors may view increased focus on AI in customer research as a sign of technological disruption that could benefit related stocks in the long term.

Key entities

  • AI Moderators

    AI tools used to conduct and analyze customer research interviews.

  • Forrester

    Publisher of the article, providing industry insights.

Related articles

$FORRMedAI 8/10

Forrester (FORR) Q2 2026 Earnings Call Transcript

Thursday, July 30, 2026 at 4:30 p.m. ET CALL PARTICIPANTS Chief Executive Officer and Chairman - George F. Colony Chief Financial Officer - Leo Christian Finn Vice President of Corporate Development, and Investor Relations - Ed Bryce Morris Chief Product Officer - Carrie Johnson Fanlo Chief Sales Officer - Christophe Favre TAKEAWAYS Total Revenue -- Forrester Research, Inc.

$FORRHigh

Forrester Research Reports 2026 Second-Quarter Financial Results

FORRESTER RESEARCH, INC. (FORR) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 FOR IMMEDIATE RELEASE Forrester Research Reports 2026 Second-Quarter Financial Results CAMBRIDGE, Mass., July 30, 2026 — Forrester Research, Inc. (Nasdaq: FORR) today announced financial results for the second quarter ended June 30, 2026, with contract value at $283.

$GMABMedAI 8/10

Genmab reports trial results for ovarian cancer drug candidate

Genmab (GMAB) reported Phase 1/2 trial results for rinatabart sesutecan in platinum-resistant ovarian cancer, showing a 45.9% response rate and median progression-free survival of 9.5 months. The trial involved 109 patients, with common side effects including fatigue, nausea, and anemia. The drug is being evaluated in four Phase 3 trials for various gynecologic cancers.

$RKLBMed

Rocket Lab Just Signed the Biggest Commercial Electron Deal in Its History. Its Launch Backlog Now Tops 100.

Rocket Lab (RKLB) secured a 20-launch deal with Synspective, its largest commercial contract, boosting its backlog to over 100 missions. Synspective's total orders now reach 47 Electron missions. The stock rose 6% post-announcement, but concerns about competition from SpaceX persist. Rocket Lab's revenue per launch increased to $9.2M in H1 2026, with costs dropping to $4.9M.